Kwality has 19 filing-ready dossiers, 21 targeted by Q1 2027

Kwality Pharmaceuticals has 19 dossiers available for global filing from its 40-product development programme, while 21 further dossiers are targeted by Q1 2027. The disclosed programme includes 11 oncology products, 27 general products and two Beta Lactam products, with seven pending dossiers scheduled by Q4 2026.

How many global-filing dossiers does Kwality have ready?

Kwality has 19 dossiers available for global filing today, out of 40 products in development. The presentation also reports 19 completed bioequivalence (BE) studies, including one in-vitro study for Azacitidine. The matching counts show that the programme currently records the same number of completed BE studies and available dossiers, although the presentation does not provide a product-by-product study-to-dossier mapping.

Kwality classifies the other 21 products as dossiers in progress. The split is 19 available dossiers, seven planned by Q4 2026 and 14 planned by Q1 2027, which totals 40 products. The presentation identifies dossier availability as the milestone; it does not state that the 19 available dossiers have been submitted, approved or launched in any market.

When does Kwality expect to complete its remaining dossiers?

Kwality expects seven of the 21 in-progress dossiers to be available by Q4 2026 and the remaining 14 by Q1 2027. This places one pending tranche in Q4 2026 and the larger tranche in Q1 2027. If the timetable is met, the available dossier count would rise from 19 to 26 after the Q4 2026 milestone and then to 40 in Q1 2027.

The schedule distinguishes products already in development from products with a dossier available for filing. All 40 products are included in the development programme today, but only 19 are marked as available. The presentation does not disclose filing countries, regulators, submission dates, review periods or expected approval dates for either the currently available dossiers or the 21 pending dossiers.

Kwality’s disclosed plan therefore has two measurable execution points: completion of seven dossiers by Q4 2026 and completion of 14 more by Q1 2027. The source provides no revenue estimate linked to either milestone. It also provides no indication of whether the 21 dossiers will be filed immediately after completion or whether filings will occur across more than one international market.

Which therapy areas make up Kwality’s development programme?

Kwality’s general portfolio contains 27 of the 40 products, compared with 11 oncology products and two Beta Lactam products. General products are therefore the largest category in the programme. The presentation divides these categories further into oral solids, injectables and, for general products, one liquid-oral product.

General oral solids are the largest individual segment, with 22 products, 10 completed BE studies and 10 dossiers available today. The segment has three dossiers planned by Q4 2026 and nine by Q1 2027, making it responsible for 12 of the 21 pending dossiers. That is more than the five pending oncology oral-solid dossiers, the two pending general injectable dossiers and the one pending general liquid-oral dossier.

Oncology oral solids include nine products, four completed BE studies and four available dossiers. Kwality schedules two further oncology oral-solid dossiers by Q4 2026 and three by Q1 2027. Oncology injectables contain two products, with one available dossier and one further dossier planned by Q4 2026.

How does dosage form affect Kwality’s dossier readiness?

Kwality’s oral-solid portfolio comprises 33 products across oncology, general and Beta Lactam categories, while injectables account for six products and liquid orals account for one product. Oral solids include 16 of the 19 available dossiers: four in oncology, 10 in general products and two in Beta Lactam. Injectables account for the remaining three available dossiers.

The two Beta Lactam oral-solid products are the only listed segment in which every product already has a completed BE study and an available dossier. Kwality lists two products, two BE studies and two available dossiers for this segment, with no dossiers scheduled for either Q4 2026 or Q1 2027. In contrast, general oral solids still have 12 dossiers pending despite being the programme’s largest segment.

General injectables include four products, two completed BE studies and two available dossiers. Kwality plans one general injectable dossier by Q4 2026 and one by Q1 2027. The single general liquid-oral product has no completed BE study or available dossier in the presentation, but its dossier is scheduled by Q1 2027.

What does Kwality disclose about filing and commercial outcomes?

Kwality discloses a development and dossier-readiness programme, rather than a regulatory approval or sales forecast. The 40 products span oncology, general medicines and Beta Lactam products, while the 19 available dossiers are described as ready for global filing. The source does not identify the intended countries, regulatory agencies or filing sequence for those 19 dossiers.

The presentation names Azacitidine as the one in-vitro study within the 19 completed BE studies. It does not state the dosage form, filing market or planned submission date for Azacitidine. Similarly, it does not state whether individual products listed elsewhere in the presentation, such as Palbociclib Tablets 125 mg or Ceftriaxone Injection 2 g, are among the 40 products in the global development programme.

The filing-readiness timetable also does not establish a launch timetable. Kwality provides no approval probability, regulatory review assumption, pricing information or sales contribution for the 19 available dossiers. The disclosed evidence supports the count and timing of development documents, but not a conclusion on commercialisation or export revenue.

Conclusion

Kwality has set out a 40-product global development programme with 19 available dossiers and 21 dossiers in progress. General oral solids are the central component, accounting for 22 products, 10 available dossiers and 12 of the 21 dossiers scheduled for completion after the current programme snapshot. Beta Lactam oral solids, by comparison, have two products and both dossiers already available.

The next disclosed checkpoints are seven additional dossiers by Q4 2026 and 14 by Q1 2027. Investors can watch whether Kwality completes those tranches on schedule, particularly the nine general oral-solid dossiers planned for Q1 2027, and whether later disclosures add filing markets, regulatory outcomes or launch plans.